Kristen Brennand

Kristen Brennand, who in her research integrates expertise in genetics, neuroscience, and stem cells to identify the mechanisms that underlie brain disease, was recently appointed the Elizabeth Mears and House Jameson Professor of Psychiatry.

She is also co-director of the Yale Science Fellows Program, a Yale School of Medicine initiative aimed at recruiting, supporting, and promoting outstanding young scientists from groups traditionally underrepresented in science and medicine.

Brennand completed her Ph.D. at Harvard University in the laboratory of the noted stem cell biologist Dr. Douglas Melton. During her postdoctoral fellowship at the Salk Institute, she drew international notice for publishing the first cellular model for schizophrenia. She developed a new method for reprogramming skin samples from patients into human induced pluripotent stem cells and then she differentiated these stem cells into neurons. Her initial report demonstrated that neurons derived from schizophrenia patients had profound deficits in synaptic connectivity, i.e., were less well connected to each other.

While on the faculty at the Icahn School of Medicine at Mount Sinai, Brennand developed a highly productive laboratory and a network of collaborations. By combining stem cell biology, psychiatric genetics, and neurobiology, she pioneered a new approach to studying brain disease. She and her collaborators shed light on the genetics and biology of schizophrenia, bipolar disorder, and other conditions. She was interim director of the Pamela Sklar Division of Psychiatric Genomics and then director of the Alper Stem Cell Center.

Although Brennand arrived at Yale during the pandemic, she rapidly established a productive laboratory, created new interdepartmental collaborations, and distinguished herself as a valued teacher and mentor. Her laboratory also is quite well funded with competitive grants from the National Institutes of Health (NIH).

She also has received numerous honors. The Brain and Behavior Research Foundation awarded her the Maltz Prize for Schizophrenia Research and elected her to its Scientific Council. This year, she was elected to the Connecticut Academy of Science and Engineering and named as a finalist for the 2022 Blavatnik Awards for Young Scientists. She also has developed a reputation as a mentor to her trainees and other young scientists. In 2019, she received the Friedman Brain Institute Neuroscience Mentorship Distinction Award. She serves as a standing member of NIH study section and the editorial boards of seven journals in psychiatry, stem cell biology, and neuroscience.

Go here to see the original:
Brennand named Elizabeth Mears and House Jameson Professor of Psychiatry - Yale News

As the 3rd presenter during the morning session of the American Society for Dermatologic Surgery Meeting, Emerging Concepts, Saranya Wyles, MD, PhD, assistant professor of dermatology, pharmacology, and regenerative medicine in the department of dermatology at the Mayo Clinic in Rochester, Minnesota, explored the hallmarks of skin aging, the root cause of aging and why it occurs, and regenerative medicine. Wyles first began with an explanation of how health care is evolving. In 21st-century health care, there has been a shift in how medical professionals think about medicine. Traditionally,the first approach was to fight diseases, such as cancer, inflammatory conditions, or autoimmune disorders. Now, the thought process is changing to a root cause approach with a curative option and how to rebuild health. Considering how to overcome the sequence of the different medications and treatments given to patients is rooted in regenerative medicine principles.

For skin aging, there is a molecular clock that bodies follow. Within the clock are periods of genomic instability, telomere attrition, and epigenetic alterations, and Wyles lab focuses on cellular senescence.

We've heard a lot atthis conference about bio stimulators, aesthetics, and how we can stimulate our internal mechanisms of regeneration. Now, the opposite force of regeneration isthe inhibitory aging hallmarks which include cellular senescence. So, what is cell senescence? This isa state that the cell goes into, similar to apoptosis or proliferation, where the cell goesinto a cell cycle arrest so instead of dividing apoptosis, leading to cell death,the cell stays in this zombie state, said Wyles.

Senescence occurs when bodies require a mutation for cancers. When the body recognizes there is something wrong, it launches itself into the senescent state, which can be beneficial. Alternatively, chronic senescence seen with inflammageing, like different intrinsic markers, extrinsic markers, and UV damage, is a sign of late senescence. Senescence cells can be melanocytes, fibroblasts, and cells that contribute to the regeneration of the skin.

I think were in a very exciting time ofinnovation and advancements in medicine, which is the meeting of longevity science of aging and regenerative medicine, said Wyles.

Regenerative medicine is a new field of medicine that uses native and bioengineered cells, devices, and engineering platforms with the goal of healing tissues and organs byrestoring form and function through innate mechanisms of healing.Stem cell therapy and stem cell application are commonly referenced with regenerative medicine. Typically, first-in-class treatments include cells, autologous or allogeneic, different types of cells that areassociated with high-cost due to the manufacturing.

With regenerative medicine, there's a new class of manufacturing. Regenerative medicine is not like traditional drugs where every product is consistent. These are cells, so the idea of manufacturing, and minimally manipulating, all comes into play. Now, there's a new shift towards next-generation care. This is cell-free technology. So, this is the idea of exosomes, because these are now products from cells that can be directly applied, they can be shelf-stable, accessible, and more cost-effective, said Wyles.

Exosomes are the ways that the cells communicate with each other. Cells have intercellularcommunications and depending on the source of the exosomes, there can be different signals. Wyles focused specifically on a platelet product, which is a pooled platelet product that can be purified and used for different mechanisms including wound healing, fat grafting, degenerative joint disease, and more.In a cosmetic studyconducted by Mayo Clinic, a topical platelet exosome product was applied to the face in the morning and the evening. Application included a 3-step regimen, a gentle cleanser, a platelet exosomeproduct, and then a sunscreen.

After 6 weeks, there was a significant improvement in redness and a 92% improvement in the hemoglobin process. Vasculature also improved across age groups. The study enrolled 56patients, and the average age was 54. Patients in their 40s, 50s, and 60s saw consistent improvement in redness and skin aging.

Lastly, Wyles stressed that as dermatologists think through the science-driven practices of these innovative strategies for skin aging, wound healing, and other regenerative approaches, they must think about responsible conducts of research. Currently, there are no FDA indications for exosomes being injected.

Reference:

See the rest here:
The Switch to Regenerative Medicine - Dermatology Times

While we love our bodies, its nice to treat ourselves to some luxurious products. This time around, our eyes are set on this massage oil that not only nourishes the skin but helps diminish the appearance of cellulite. Now we love every cranny of our bodies, but for those that dont like it as much, heres a more affordable way of going about it.

Now for October Prime Day 2022, this Amazon-beloved massage oil is an impressive 61 percent off for Prime Members. Thats right, the M3 Naturals Anti Cellulite Massage Oil is on sale, and were obsessed with it right now.

Provided by SheKnows Courtesy of M3 Naturals - Credit: M3 Naturals.M3 Naturals.

Infused with collagen and stem cells, this natural massage oil contains rich ingredients like grapefruit, grapeseed, eucalyptus, and lemon citrus essential oils. Why so many ingredients? Well, not only does it fight cellulite, but it moisturizes and tones the skin. Good for any skin type, this oil makes skin look healthier and more toned.

With nearly 58,000 reviews at 4.3 stars, this oil has grown a cult following and the before and after photos are insane. Not only are the photos are insane, but the reviews are glowing. One Amazon reviewer whos a proud twin mama said, I was very skeptical at first, but seeing the difference in these photos is proof that it does wonders. I would definitely recommend this product!

Another reviewer added, Im SO glad I decided to take a chance on all the great reviews and try this product, the picture speaks for itselfI used it every day once a day for 2 months and I still have about 1/3 of the bottle remaining. I HIGHLY recommend!

Click here to read the full article.

Follow this link:
Last Chance to Get The Collagen-Infused Massage Oil That Moisturizes Skin & Diminishes Cellulite For Less Than $20 - msnNOW

As described by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), symptoms of Addison's disease progress slowly. Additionally, some of them are shared by other conditions, making the disease difficult to diagnose.Since the onset of symptoms can occur during potentially fatal adrenal crisis, early detection of signs and symptoms followed by treatment is critical.

People with Addison's disease predominantly experience long-lasting fatigue, muscle weakness, loss of appetite, abdominal pain, and weight loss. Per WebMD, other symptoms include nausea, vomiting, diarrhea, moodiness, irritability, depression, heat or cold intolerance, salt cravings, and poor stress management. Some people have low blood sugar while others experience low blood pressure when standing (postural hypotension), potentially causing dizziness or fainting.

Darkening or freckling of the skin, particularly visible in sun exposed skin, is also seen in people with Addison's disease. This blotchy, darkened skin has a greater tendency to occur on the forehead, knees, and elbows, as well as on scars, gums, skin folds, and creases (e.g., palms).

Visit link:
Addison's Disease Explained: Causes, Symptoms, And Treatments - Health Digest

Novel name reflects expansion of capabilities and solutions Novel name reflects expansion of capabilities and solutions

Go here to see the original:
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager of the logistic company « Road Runner » was acting as a consultant for ISI until now and becomes ISOTOPES SERVICES INTERNATIONAL (ISI) shareholder.

View original post here:
Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER

TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials New England 2022, October 12-13 in Boston, MA.

Read this article:
Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022

VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has initiated a program aimed at advancing its topical treatments for precancerous skin conditions such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma through to the clinic. One in every three cancers diagnosed worldwide is skin cancer, with non-melanoma skin cancers the most common of all types of cancer, representing a significant market opportunity. According to a report by Grand View Research, Inc, the global actinic keratosis treatment market size alone is expected to reach $8.12 billion USD by 2028.

Here is the original post:
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing...

Liège, Belgium – 12 October 2022 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced it has moved its headquartered operations to LégiaPark, in the heart of the life sciences industry ecosystem of Liege, within the Wallonia region. LégiaPark is a new modern complex operating with environmental responsibility and hosts life science companies.

Original post:
Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its...

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

View post:
VectivBio Announces Date of Extraordinary General Meeting of Shareholders

AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.

Read more here:
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer

NEW YORK and MAINZ, GERMANY, OCTOBER 12, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age. Pending recommendation from the Centers for Disease Control and Prevention (CDC), 10-µg doses will be shipped immediately.

See the rest here:
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through...

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

See more here:
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

CALGARY, Alberta, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide.

Here is the original post:
Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022. The posters will share findings from several studies surrounding adintrevimab, including data from the Phase 1 and Phase 2/3 clinical trials.

See the original post here:
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”). AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039.

See the article here:
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced...

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

Follow this link:
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences:

View original post here:
23andMe to Present at Upcoming Investor Conferences

Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in Q1 2023

Here is the original post:
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track

Go here to see the original:
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2